Osimertinib combined bevacizumab in untreated epidermal growth factor receptor mutaeted non-small-cell lung cancer patients with malignant pleural and/or pericardial effusion -phase II trial-
Latest Information Update: 15 Jul 2021
At a glance
- Drugs Bevacizumab (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SPIRAL II Study
- 10 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 07 Jul 2020 Planned End Date changed from 30 Sep 2021 to 31 Jan 2023.
- 07 Jan 2019 Planned number of patients changed from 36 to 30.